Thursday, June 25, 2026
LEXEO THERAPEUTICS ANNOUNCES REGULATORY UPDATE AND REGISTRATIONAL TRIAL DESIGN FOR LX2006 GENE THERAPY IN FRIEDREICH ATAXIA
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, today announced that the Company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) intended to provide clinical evidence to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for gene therapy candidate LX2006 under the accelerated approval pathway in 2028.
